Chunyan Hou

Chunyan Hou

Auto-generated profile, based on publicly available information

Chunyan Hou

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
HZHemeng Zhang
Hemeng Zhang
JMJialin Ma
Jialin Ma
CHChunyan Hou
Chunyan Hou
XLXuehui Luo
Xuehui Luo
SZShiya Zhu
Shiya Zhu
HPHuadong Pei
Huadong Pei

12 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CHChunyan Hou
Chunyan Hou
JDJingtao Deng
Jingtao Deng
CWCi Wu
Ci Wu
JZJing Zhang
Jing Zhang
SBStephen Byers
Stephen Byers
JMJunfeng Ma
Junfeng Ma
As a unique type of glycosylation, O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) on Ser/Thr residues of proteins was discovered 40 y ago. O-GlcNAcylation is catalyzed by two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which add and remove O-GlcNAc, respectively. O-GlcNAcylation is an essential glycosylation that regulates the functions of many proteins in virtually all cellular processes. However, deep and site-specific characterization of O-GlcNAcylated proteins remains a challenge. We developed an ultradeep O-GlcNAc proteomics workflow by integrating digestion with multiple proteases, two mass spectrometric approaches (i.e., electron-transfer/higher-energy collision dissociation [EThcD] and HCD product-dependent electron-transfer/higher-energy collision dissociation [HCD-pd-EThcD]), and two data analysis tools (i.e., MaxQuant and Proteome Discoverer). The performance of this strategy was benchmarked by the analysis of whole lysates from PANC-1 (a pancreatic cancer cell line). In total, 2,831 O-GlcNAc sites were unambiguously identified, representing the largest O-GlcNAc dataset of an individual study reported so far. Unexpectedly, in addition to confirming known sites and identifying many other sites of Ser/Thr modification, O-GlcNAcylation was found on 121 tyrosine (Tyr) residues of 93 proteins. In vitro enzymatic assays showed that OGT catalyzes the transfer of O-GlcNAc onto Tyr residues of peptides and OGA catalyzes its removal. Taken together, our work reveals widespread O-GlcNAcylation on Tyr residues of proteins and that Tyr O-GlcNAcylation is mediated by OGT and OGA. As another form of glycosylation, Tyr O-GlcNAcylation is likely to have important regulatory roles.

1 February 2018 in Carbohydrate Polymers
Verified
Journal Article
Closed access
ZWZhaojie Wang
Zhaojie Wang
YQYuanhao Qiu
Yuanhao Qiu
CHChunyan Hou
Chunyan Hou
DWDongdong Wang
Dongdong Wang
FSFeifei Sun
Feifei Sun
JDJinyou Duan
Jinyou Duan

6 December 2023 in Journal of Proteome Research
Verified
Journal Article
Closed access
FHFengzhu Hu
Fengzhu Hu
WLWeiyu Li
Weiyu Li
YLYaoxiang Li
Yaoxiang Li
CHChunyan Hou
Chunyan Hou
JMJunfeng Ma
Junfeng Ma
CJCangzhi Jia
Cangzhi Jia

20 September 2024 in Journal of Proteome Research
Verified
Journal Article
Open access
CHChunyan Hou
Chunyan Hou
CWCi Wu
Ci Wu
ZWZichun Wu
Zichun Wu
YCYifan Cheng
Yifan Cheng
WLWeiyu Li
Weiyu Li
JMJunfeng Ma
Junfeng Ma
O-Linked β-N-acetylglucosamine (O-GlcNAc) modification (i.e., O-GlcNAcylation) on proteins plays critical roles in the regulation of diverse biological processes. However, protein O-GlcNAcylation analysis, especially at a large scale, has been a challenge. So far, a number of enrichment materials and methods have been developed for site-specific O-GlcNAc proteomics in different biological settings. Despite the presence of multiple methods, their performance for the O-GlcNAc proteomics is largely unclear. In this work, by using the lysates of PANC-1 cells (a pancreatic cancer cell line), we provided a head-to-head comparison of three affinity enrichment methods and materials (i.e., antibody, lectin AANL6, and an OGA mutant) for site-specific O-GlcNAc proteomics. The enriched peptides were analyzed by HCD product-dependent EThcD (i.e., HCD-pd-EThcD) mass spectrometry. The resulting data files were processed by three different data analysis packages (i.e., Sequest HT, Byonic, and FragPipe). Our data suggest that each method captures a subpopulation of the O-GlcNAc proteins. Besides the enrichment methods, we also observe complementarity between the different data analysis tools. Thus, combining different approaches holds promise for enhanced coverage of O-GlcNAc proteomics.

12 February 2025 in Cancer Research
Verified
Journal Article
Closed access
SZShuyan Zhou
Shuyan Zhou
YZYi Zhang
Yi Zhang
JBJulie Belmar
Julie Belmar
CHChunyan Hou
Chunyan Hou
YZYaqin Zhang
Yaqin Zhang
WZWenge Zhu
Wenge Zhu
Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial in regulating cell-cycle progression and cancer development. Targeting CDK4/6 has shown considerable promise in treating various cancers, including breast cancer. Despite significant therapeutic efficacy, resistance to CDK4/6 inhibitors (CDK4/6i), such as palbociclib, remains a substantial hurdle in clinical practice. Using a coculture system, cytokine array, and quantitative high-throughput combinatorial screening, we discovered a mechanism by which the Runt-related transcription factor (RUNX) 1–platelet-derived growth factor (PDGF)-BB axis regulates palbociclib resistance in breast cancer cells. Specifically, RUNX1 functioned as a transcription factor to drive expression of PDGFB, leading to resistance to palbociclib by enhancing the Akt pathway and suppressing senescence. Furthermore, in resistant cells, RUNX1 was O-GlcNAcylated at serine 252 by O-GlcNAc transferase, resulting in the stabilization of RUNX1 by preventing ubiquitin-mediated degradation. Inhibition of the RUNX1–PDGF-BB axis by specific inhibitors overcame palbociclib resistance both in vitro and in vivo. Notably, the RUNX1–PDGF-BB axis was upregulated in resistant patient-derived xenograft lines and in patients with breast cancer following treatment with CDK4/6i. These findings not only unveil O-GlcNAcylation–mediated activation of a RUNX1–PDGF-BB pathway as a driver of palbociclib resistance but also provide clinical evidence supporting the repurposing of FDA-approved PDGFR inhibitors as a therapeutic strategy to treat patients with CDK4/6i-resistant breast cancer. Significance: RUNX1-PDGF-BB signaling drives resistance to CDK4/6 inhibition in breast cancer, providing the foundation to develop approaches to target the RUNX1-PDGF-BB axis to overcome CDK4/6 inhibitor resistance in breast cancer patients.